S&P 500   5,130.85 (-0.12%)
DOW   39,004.16 (-0.21%)
QQQ   445.06 (-0.12%)
AAPL   175.74 (-2.18%)
MSFT   414.27 (-0.30%)
META   501.65 (-0.13%)
GOOGL   133.06 (-2.98%)
AMZN   179.80 (+0.89%)
TSLA   196.20 (-3.18%)
NVDA   840.37 (+2.14%)
NIO   5.40 (-6.57%)
AMD   209.88 (+3.57%)
BABA   72.30 (-3.11%)
T   16.76 (-1.30%)
F   12.65 (+1.61%)
MU   94.95 (-0.21%)
CGC   3.14 (-2.18%)
GE   160.69 (+1.29%)
DIS   112.14 (+0.17%)
AMC   4.23 (-2.98%)
PFE   25.88 (-2.67%)
PYPL   60.39 (-0.25%)
XOM   105.60 (-0.23%)
S&P 500   5,130.85 (-0.12%)
DOW   39,004.16 (-0.21%)
QQQ   445.06 (-0.12%)
AAPL   175.74 (-2.18%)
MSFT   414.27 (-0.30%)
META   501.65 (-0.13%)
GOOGL   133.06 (-2.98%)
AMZN   179.80 (+0.89%)
TSLA   196.20 (-3.18%)
NVDA   840.37 (+2.14%)
NIO   5.40 (-6.57%)
AMD   209.88 (+3.57%)
BABA   72.30 (-3.11%)
T   16.76 (-1.30%)
F   12.65 (+1.61%)
MU   94.95 (-0.21%)
CGC   3.14 (-2.18%)
GE   160.69 (+1.29%)
DIS   112.14 (+0.17%)
AMC   4.23 (-2.98%)
PFE   25.88 (-2.67%)
PYPL   60.39 (-0.25%)
XOM   105.60 (-0.23%)
S&P 500   5,130.85 (-0.12%)
DOW   39,004.16 (-0.21%)
QQQ   445.06 (-0.12%)
AAPL   175.74 (-2.18%)
MSFT   414.27 (-0.30%)
META   501.65 (-0.13%)
GOOGL   133.06 (-2.98%)
AMZN   179.80 (+0.89%)
TSLA   196.20 (-3.18%)
NVDA   840.37 (+2.14%)
NIO   5.40 (-6.57%)
AMD   209.88 (+3.57%)
BABA   72.30 (-3.11%)
T   16.76 (-1.30%)
F   12.65 (+1.61%)
MU   94.95 (-0.21%)
CGC   3.14 (-2.18%)
GE   160.69 (+1.29%)
DIS   112.14 (+0.17%)
AMC   4.23 (-2.98%)
PFE   25.88 (-2.67%)
PYPL   60.39 (-0.25%)
XOM   105.60 (-0.23%)
S&P 500   5,130.85 (-0.12%)
DOW   39,004.16 (-0.21%)
QQQ   445.06 (-0.12%)
AAPL   175.74 (-2.18%)
MSFT   414.27 (-0.30%)
META   501.65 (-0.13%)
GOOGL   133.06 (-2.98%)
AMZN   179.80 (+0.89%)
TSLA   196.20 (-3.18%)
NVDA   840.37 (+2.14%)
NIO   5.40 (-6.57%)
AMD   209.88 (+3.57%)
BABA   72.30 (-3.11%)
T   16.76 (-1.30%)
F   12.65 (+1.61%)
MU   94.95 (-0.21%)
CGC   3.14 (-2.18%)
GE   160.69 (+1.29%)
DIS   112.14 (+0.17%)
AMC   4.23 (-2.98%)
PFE   25.88 (-2.67%)
PYPL   60.39 (-0.25%)
XOM   105.60 (-0.23%)

Unicycive Therapeutics (UNCY) Competitors

$1.62
+0.02 (+1.25%)
(As of 09:40 AM ET)

UNCY vs. HCWB, CARA, AADI, TLSA, CKPT, CLNN, SCTL, BCTX, DARE, and IPA

Should you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include HCW Biologics (HCWB), Cara Therapeutics (CARA), Aadi Bioscience (AADI), Tiziana Life Sciences (TLSA), Checkpoint Therapeutics (CKPT), Clene (CLNN), Societal CDMO (SCTL), BriaCell Therapeutics (BCTX), Daré Bioscience (DARE), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "pharmaceutical preparations" industry.

Unicycive Therapeutics vs.

Unicycive Therapeutics (NASDAQ:UNCY) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.

HCW Biologics has higher revenue and earnings than Unicycive Therapeutics. HCW Biologics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unicycive Therapeutics$950K58.53-$18.06M-$1.74-0.92
HCW Biologics$6.72M8.19-$14.90M-$0.55-2.78

Unicycive Therapeutics presently has a consensus price target of $8.30, indicating a potential upside of 418.75%. HCW Biologics has a consensus price target of $9.00, indicating a potential upside of 488.24%. Given HCW Biologics' higher probable upside, analysts plainly believe HCW Biologics is more favorable than Unicycive Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
HCW Biologics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

52.5% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of HCW Biologics shares are owned by institutional investors. 42.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 45.3% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 1 more articles in the media than HCW Biologics. MarketBeat recorded 3 mentions for Unicycive Therapeutics and 2 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 0.94 beat Unicycive Therapeutics' score of 0.75 indicating that HCW Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Unicycive Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
HCW Biologics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Unicycive Therapeutics has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Unicycive Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -689.97%. Unicycive Therapeutics' return on equity of 0.00% beat HCW Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Unicycive TherapeuticsN/A N/A -97.86%
HCW Biologics -689.97%-64.43%-47.71%

Unicycive Therapeutics received 7 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 56.52% of users gave Unicycive Therapeutics an outperform vote.

CompanyUnderperformOutperform
Unicycive TherapeuticsOutperform Votes
13
56.52%
Underperform Votes
10
43.48%
HCW BiologicsOutperform Votes
6
100.00%
Underperform Votes
No Votes

Summary

Unicycive Therapeutics beats HCW Biologics on 9 of the 17 factors compared between the two stocks.


Get Unicycive Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UNCY vs. The Competition

MetricUnicycive TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$55.60M$6.61B$4.78B$7.57B
Dividend YieldN/A2.83%5.37%3.87%
P/E Ratio-0.9212.59250.0518.52
Price / Sales58.53235.783,009.5177.90
Price / CashN/A19.1792.8055.40
Price / Book-53.334.714.474.73
Net Income-$18.06M$154.88M$109.38M$209.68M
7 Day Performance1.27%7.99%115.41%3.63%
1 Month Performance71.54%19.52%127.31%9.16%
1 Year Performance226.53%9.91%133.82%8.30%

Unicycive Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCWB
HCW Biologics
2.0756 of 5 stars
$1.46
+5.8%
$9.00
+516.4%
-14.0%$52.52M$6.72M-2.6544Positive News
CARA
Cara Therapeutics
4.744 of 5 stars
$0.95
+17.4%
$12.79
+1,252.3%
-90.8%$51.51M$41.87M-0.44106Short Interest ↓
Gap Up
AADI
Aadi Bioscience
2.9064 of 5 stars
$2.07
+4.5%
$24.67
+1,091.6%
-79.4%$50.78M$15.22M-0.8888Short Interest ↓
Gap Up
TLSA
Tiziana Life Sciences
0 of 5 stars
$0.49
-2.0%
N/A-14.2%$50.61MN/A0.009Gap Down
CKPT
Checkpoint Therapeutics
3.7866 of 5 stars
$2.14
+4.9%
$22.60
+956.1%
-57.1%$50.35M$190,000.000.0024Gap Up
CLNN
Clene
2.0629 of 5 stars
$0.43
flat
$7.80
+1,735.3%
-67.6%$54.58M$470,000.00-0.9275Upcoming Earnings
SCTL
Societal CDMO
2.6389 of 5 stars
$0.52
-3.7%
$1.88
+259.2%
-13.7%$54.70M$90.21M-1.74275Upcoming Earnings
Short Interest ↓
BCTX
BriaCell Therapeutics
2.1452 of 5 stars
$3.43
+4.6%
$18.00
+424.8%
-53.4%$54.81MN/A-1.9716Short Interest ↓
DARE
Daré Bioscience
2.7727 of 5 stars
$0.50
+16.3%
$6.00
+1,098.8%
-52.2%$49.33M$10M-1.0625Positive News
IPA
ImmunoPrecise Antibodies
2.023 of 5 stars
$1.86
flat
$8.00
+330.1%
-56.0%$48.96M$15.61M-3.96102

Related Companies and Tools

This page (NASDAQ:UNCY) was last updated on 3/4/2024 by MarketBeat.com Staff